Firefly Neuroscience shares rise 30.36% in intraday after announcing partnership with U.S. War Department to deploy AI EEG platform for military PTSD and TBI.

Firefly Neuroscience surged 30.36% in intraday trading after announcing a public-private partnership with the U.S. Department of Defense to deploy its FDA 510k-licensed AI-driven EEG/ERP technology platform for assessing and treating PTSD and TBI in military personnel, expanding its footprint into the U.S. government and defense health sectors.